|
Mechanismα1A-AR antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date07 Aug 1987 |
[Translation] Study on the bioequivalence of terazosin hydrochloride tablets in healthy volunteers
本试验为正式试验,旨在研究单次空腹口服海南绿岛制药有限公司研制、生产的盐酸特拉唑嗪片(2 mg)的药代动力学特征;以Aesica Queenborough Limited生产的盐酸特拉唑嗪片(Hytrin®,2 mg)为参比制剂,比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞、Tmax,评价两制剂的生物等效性。
[Translation] This is a formal trial, which aims to study the pharmacokinetic characteristics of a single fasting oral administration of terazosin hydrochloride tablets (2 mg) developed and produced by Hainan Ludao Pharmaceutical Co., Ltd.; using terazosin hydrochloride tablets (Hytrin®, 2 mg) produced by Aesica Queenborough Limited as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞, and Tmax of the two preparations were compared, and the bioequivalence of the two preparations was evaluated.
100 Clinical Results associated with Hainan Green Island Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hainan Green Island Pharmaceutical Co., Ltd.
100 Deals associated with Hainan Green Island Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hainan Green Island Pharmaceutical Co., Ltd.